IMS 2023 | The importance of MRD as a prognostic tool in multiple myeloma
Michele Cavo
• 28 Sep 2023
Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, discusses the applications of measurable residual disease (MRD) in multiple myeloma. MRD has been proven to be a strong predictor of response in multiple myeloma and there are numerous assessment techniques such as flow cytometry and next-generation sequencing (NGS). Prof. Cavo additionally highlights the importance of imaging, as well as maintaining MRD negativity in patients who achieve it. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
